BeStock  
Stocks › ETON

Eton Pharmaceutical ETON

US equityMarket cap rank #2940
$55.62 +$0.26 (+0.47%)
Pre-market · Oct 6, 7:10 am ET · After hours $55.62 0.00%
Open$55.85
Prev close$55.36
Day range$54.50 – $56.86
Volume405.5K
Market cap$1.59B
P/E (TTM)142.6
Dividend yield–

ETON Stock News

Headlines matching Eton Pharmaceutical or the ETON ticker, most recent first.

  • Eton Pharmaceuticals Announces U.S. Commercial Availability of IMPAVIDO (Miltefosine) CapsulesGlobeNewswire · 28 Sep 2026
  • Eton Pharmaceutical(ETON.US) Officer Sells US$6.09 Million in Common StockMarket news · 21 Aug 2026
  • Upgrade: Analysts Just Made A Notable Increase To Their Eton Pharmaceuticals, Inc. (NASDAQ:ETON) ForecastsSimply Wall St · 19 Aug 2026
  • B. Riley Adjusts Price Target on Eton Pharmaceuticals to $70 From $40, Maintains Buy RatingMT Newswires · 14 Aug 2026
  • H.C. Wainwright Maintains Eton Pharmaceutical(ETON.US) With Buy Rating, Raises Target Price to $70Market news · 14 Aug 2026
  • Craig-Hallum Maintains Eton Pharmaceutical(ETON.US) With Buy Rating, Raises Target Price to $76Market news · 14 Aug 2026
  • Craig-Hallum Maintains Eton Pharmaceutical(ETON.US) With Buy Rating, Maintains Target Price $62Market news · 13 Aug 2026
  • H.C. Wainwright Maintains Eton Pharmaceutical(ETON.US) With Buy Rating, Raises Target Price to $65Market news · 11 Aug 2026
  • 4: Eton Pharmaceutical | 4: Statement of changes in beneficial ownership of securities-10% Owner Opaleye Management Inc.SEC · 8 Jul 2026
  • CCORF Maintains Eton Pharmaceutical(ETON.US) With Buy Rating, Maintains Target Price $60Market news · 30 Jul 2026
  • Craig-Hallum Maintains Eton Pharmaceutical(ETON.US) With Buy Rating, Announces Target Price $62Market news · 28 Jul 2026
  • 4/A: Eton Pharmaceutical | 4/A: Statement of changes in beneficial ownership of securities (and amendment thereto)-10% Owner Opaleye Management Inc.SEC · 18 Jul 2026
  • CCORF Initiates Eton Pharmaceutical(ETON.US) With Buy Rating, Announces Target Price $60Market news · 17 Jul 2026
  • 4: Eton Pharmaceutical | 4: Statement of changes in beneficial ownership of securities-10% Owner Opaleye Management Inc.SEC · 17 Jul 2026
  • B. Riley Securities Maintains Eton Pharmaceutical(ETON.US) With Buy Rating, Maintains Target Price $40Market news · 27 Jun 2026

Discussion

No comments yet — be the first to weigh in on ETON.

Leave a comment

Scroll to Top